The modern workplace is evolving, and so is our understanding of substance use disorders. This is especially true for opioid use disorder (OUD), a chronic disease with both medical and psychological aspects. As employers face ongoing challenges with recruitment, retention, and productivity, one of the most overlooked opportunities is supporting employees in recovery, including those participating in medication‑assisted treatment (MAT).
MAT, using FDA‑approved medications such as buprenorphine, methadone, or naltrexone alongside counseling, is considered the gold standard for treating both the physical and psychological addiction of OUD. But in many organizations, drug testing policies haven’t kept up with treatment advances. And stigma remains another barrier to recovery.
Far from being a liability, employees in recovery who are undergoing MAT often bring resilience, loyalty, and a strong commitment to their work. Backed by federal guidance and public health research, the case for supporting these employees is both ethical and business‑smart.
MAT Is an Evidence‑Based, Effective Treatment, Not a Substitute Addiction
According to the Centers for Disease Control and Prevention (CDC), MAT is a clinically proven approach that reduces withdrawal symptoms, stabilizes brain chemistry, and helps individuals regain daily function. It significantly lowers the risk of relapse and overdose, improves long‑term recovery outcomes, and supports sustained employment.
The CDC notes that MAT helps people “return to a healthy, productive life” and is associated with improved social functioning and reduced criminal activity. In other words, MAT is not a shortcut—it’s a structured medical and therapeutic treatment that enables people to recover and thrive.
Why this matters for employers: Employees who receive effective treatment are more reliable, more productive, and more likely to stay with their employer long‑term.
Federal Law Protects Employees Undergoing MAT
The U.S. Equal Employment Opportunity Commission (EEOC) makes it clear: employees taking legally prescribed opioids or participating in MAT for opioid use disorder are protected under the Americans with Disabilities Act (ADA).
The EEOC states that employers cannot discriminate against employees simply because they use medications such as buprenorphine or methadone as part of treatment. Employees are also entitled to reasonable accommodation if their condition qualifies as a disability.
Examples of reasonable accommodation may include:
- Compliant drug testing and interpretation of results
- Adjusted schedules for counseling or medical appointments
- Temporary reassignment of safety‑sensitive tasks if medically necessary
- Clear, individualized assessments rather than assumptions about impairment
Why this matters for employers: Understanding ADA protections reduces legal risk and fosters a fair and compliant workplace culture.
Employees in Recovery Are Often Among the Most Dedicated Workers
People who have gone through treatment, especially those committed to MAT, tend to be highly motivated to rebuild their lives and careers. Many employers report that workers in recovery demonstrate:
- Strong loyalty to supportive employers
- High levels of perseverance and problem‑solving
- Deep appreciation for stability and routine
- Lower turnover when compared to the general workforce
Why this matters for employers: Supporting employees in recovery isn’t charity – it’s smart talent management.
Stigma Is the Real Barrier, Not MAT
Despite decades of research, stigma remains one of the greatest obstacles for people in recovery. Misconceptions—such as the idea that MAT “replaces one drug with another”—are outdated and medically inaccurate.
The CDC emphasizes that MAT does not substitute one addiction for another. Instead, it treats OUD as a chronic medical condition, similar to how insulin treats diabetes.
When employers reduce stigma, they create a culture where employees feel safe seeking help early, before crises occur.
Why this matters for employers: A stigma‑free environment reduces absenteeism, improves morale, and strengthens organizational culture.
Supporting MAT Reduces Costs and Improves Productivity
Untreated substance use disorders cost U.S. employers billions annually through absenteeism, turnover, healthcare expenses, and lost productivity. Employees in stable recovery, especially those supported through MAT, are far less likely to experience these disruptions.
Research consistently shows that:
- Employees in recovery have lower healthcare costs over time
- Treatment reduces absenteeism and presenteeism
- Retention improves when employers adopt supportive policies
Why this matters for employers: Investing in recovery support is far less costly than turnover, recruitment, and lost productivity.
A Supportive Workplace Strengthens Community Impact
Employers play a powerful role in reducing stigma and supporting recovery in the broader community. When workplaces embrace evidence‑based treatment and recovery‑friendly policies, they:
- Help reduce overdose deaths
- Strengthen families and communities
- Demonstrate leadership in public health
- Attract socially responsible partners and customers
Why this matters for employers: Supporting employees in MAT isn’t just good business, it’s good citizenship.
Recovery‑Friendly Workplaces Are the Future
Employees in recovery who participate in medication‑assisted treatment are not liabilities—they are assets. Backed by federal protections and strong clinical evidence, MAT helps individuals regain stability, maintain employment, and contribute meaningfully to their workplaces.
Employers who embrace recovery‑friendly practices benefit from:
- Higher retention
- Lower costs
- Stronger workplace culture
- Reduced legal risk
- A healthier, more resilient workforce
By understanding the science, following federal guidance, and reducing stigma, employers can play a transformative role in supporting recovery, and strengthening their organizations in the process.
Debra J. Stevens, President & Founder, The Brand Voice
Debra Stevens is a seasoned brand-builder and storyteller with decades of experience crafting content that resonates, inspires, and builds lasting connections with audiences. Following 40 years of experience leading marketing for companies, healthcare systems and nonprofit organizations, she founded The Brand Voice, a boutique marketing agency specializing in brand strategy and development, executive communication and other content creation. She is a founding member of Valley Leadership’s Opioid Use Disorder Stigma Reduction Impact Maker.
References
- Centers for Disease Control and Prevention. Medication-Assisted Treatment for Opioid Use Disorder. https://www.cdc.gov/overdose-resources/files/medication-assisted-treatment-for-opioid-use-disorder.html
- U.S. Equal Employment Opportunity Commission. Use of Codeine, Oxycodone, and Other Opioids: Information for Employees. https://www.eeoc.gov/laws/guidance/use-codeine-oxycodone-and-other-opioids-information-employees
- Legal Clarity. Employment Law:ADA Drug Testing Rules and Addiction Protections at Work. https://legalclarity.org/ada-drug-testing-rules-and-addiction-protections-at-work/